ranolazine has been researched along with Alloxan Diabetes in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| El-Gawly, HW; El-Sherbeeny, NA; Elaidy, SM; Elkholy, SE; Toraih, EA | 1 |
| Khazraei, H; Mirkhani, H; Shabbir, W | 1 |
| Bai, Y; Chen, X; Dong, C; Jiang, Y; Jiao, J; Liu, X; Qin, Y; Qu, H; Ren, L; Sun, X; Wang, S; Yang, B | 1 |
| Chang, GJ; Chang, PC; Chou, CC; Chu, Y; Lee, HL; Liu, HT; Wen, MS; Wo, HT; Yen, TH | 1 |
| Imenshahidi, M; Kamali, H; Mashayekhi-Sardoo, H; Mehri, S; Mohammadpour, AH; Sahebkar, A | 1 |
| Ameen, AM; Tawfik, MK | 1 |
| Khazraei, H; Mirkhani, H; Purkhosrow, A | 1 |
| Belardinelli, L; Dhalla, AK; Galanopoulos, G; Kostakou, E; Mantzouratou, P; Mourouzis, I; Pantos, C | 1 |
| Belardinelli, L; Dhalla, AK; Kahlig, KM; Krause, M; Ning, Y; Rajamani, S; Yang, M | 1 |
| Khazraei, H; Mirkhani, H; Shafa, M | 1 |
| Bronsart, LL; Contag, CH; Stokes, C | 1 |
| Belardinelli, L; Dhalla, AK; Fu, Z; Jiang, J; Liu, D; Ning, Y; Zhen, W | 1 |
12 other study(ies) available for ranolazine and Alloxan Diabetes
| Article | Year |
|---|---|
Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ.
Topics: Animals; Behavior, Animal; Comorbidity; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Hyperalgesia; Inflammation; Interleukin-1beta; Male; NAV1.7 Voltage-Gated Sodium Channel; Neuroprotective Agents; Pioglitazone; PPAR gamma; Ranolazine; Rats; Rats, Wistar; Spinal Cord; Tumor Necrosis Factor-alpha | 2020 |
Electrocardiological effects of ranolazine and lidocaine on normal and diabetic rat atrium.
Topics: Acetanilides; Action Potentials; Animals; Diabetes Mellitus, Experimental; Lidocaine; Piperazines; Ranolazine; Rats; Sodium Channel Blockers | 2021 |
Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1/NRG1 pathway.
Topics: Animals; Apoptosis; Blood Glucose; Cardiovascular Agents; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dose-Response Relationship, Drug; Male; Neuregulin-1; Ranolazine; Rats; Rats, Sprague-Dawley; Receptor, Notch1; Signal Transduction | 2020 |
Mechanisms of ranolazine pretreatment in preventing ventricular tachyarrhythmias in diabetic db/db mice with acute regional ischemia-reperfusion injury.
Topics: Action Potentials; Animals; Calcium; Calcium-Binding Proteins; Cardiovascular Agents; Diabetes Mellitus, Experimental; Female; Heart Rate; Mice; Myocardial Reperfusion Injury; Ranolazine; Tachycardia, Ventricular | 2020 |
Diabetes mellitus aggravates ranolazine-induced ECG changes in rats.
Topics: Animals; Diabetes Mellitus, Experimental; Electrocardiography; Humans; Male; Ranolazine; Rats; Rats, Wistar | 2022 |
Cardioprotective effect of ranolazine in nondiabetic and diabetic male rats subjected to isoprenaline-induced acute myocardial infarction involves modulation of AMPK and inhibition of apoptosis.
Topics: Acute Disease; AMP-Activated Protein Kinases; Animals; Apoptosis; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Experimental; Electrocardiography; Glycated Hemoglobin; Isoproterenol; Male; Myocardial Infarction; Oxidative Stress; Ranolazine; Rats; Rats, Wistar | 2019 |
Vasorelaxant effect of ranolazine on isolated normal and diabetic rat aorta: a study of possible mechanisms.
Topics: Acetanilides; Animals; Aorta; Diabetes Mellitus, Experimental; Enzyme Inhibitors; In Vitro Techniques; Male; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Vasodilation | 2013 |
The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats.
Topics: Acetanilides; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Echocardiography; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Heart Function Tests; Insulin; Male; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Ranolazine; Rats; Rats, Wistar; Treatment Outcome; Ventricular Function, Left | 2014 |
Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects.
Topics: Acetanilides; Animals; Diabetes Mellitus, Experimental; Exocytosis; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Islets of Langerhans; Male; NAV1.3 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers | 2014 |
Effect of ranolazine on cardiac microcirculation in normal and diabetic rats.
Topics: Acetanilides; Animals; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Diabetes Mellitus, Experimental; Heart Rate; Injections, Intravenous; Laser-Doppler Flowmetry; Male; Microcirculation; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Time Factors | 2014 |
Chemiluminescence Imaging of Superoxide Anion Detects Beta-Cell Function and Mass.
Topics: Animals; Cell Respiration; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucose; HeLa Cells; Humans; Hyperglycemia; Imaging, Three-Dimensional; Imidazoles; Insulin-Secreting Cells; Luminescent Measurements; Mice, Inbred NOD; Organ Size; Pyrazines; Pyridines; Ranolazine; Superoxides | 2016 |
Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice.
Topics: Acetanilides; Animals; Apoptosis; B-Lymphocytes; Blood Glucose; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Piperazines; Ranolazine; Rats | 2011 |